Compare STAA & KBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STAA | KBDC |
|---|---|---|
| Founded | 1982 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 867.9M | 918.9M |
| IPO Year | 1995 | 2018 |
| Metric | STAA | KBDC |
|---|---|---|
| Price | $25.63 | $14.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $22.81 | $15.40 |
| AVG Volume (30 Days) | ★ 1.3M | 282.1K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 12.97% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.67 |
| Revenue | ★ $239,442,000.00 | N/A |
| Revenue This Year | $28.87 | $193.84 |
| Revenue Next Year | $7.49 | $9.00 |
| P/E Ratio | ★ N/A | $8.78 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.59 | $13.06 |
| 52 Week High | $30.81 | $16.40 |
| Indicator | STAA | KBDC |
|---|---|---|
| Relative Strength Index (RSI) | 68.90 | 66.39 |
| Support Level | $23.79 | $14.01 |
| Resistance Level | $27.52 | $15.00 |
| Average True Range (ATR) | 1.18 | 0.31 |
| MACD | 0.38 | 0.09 |
| Stochastic Oscillator | 84.91 | 92.34 |
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company, investing mainly in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation mainly through debt investments in middle-market companies.